Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Show more

Location: 1325 Avenue of Americas, New York, NY, 10019, United States | Website: https://www.brainstorm-cell.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

11.81M

52 Wk Range

$0.72 - $6.45

Previous Close

$1.22

Open

$1.23

Volume

251,799

Day Range

$1.18 - $1.25

Enterprise Value

9.018M

Cash

1.644M

Avg Qtr Burn

-1.915M

Insider Ownership

15.98%

Institutional Own.

12.89%

Qtr Updated

03/31/25